Ibogaine

Iboga, ibogaine, noribogaine & 18-MC

 

 

Jump to:

 

 

Helsley, Rabin & Winter (1998). The effects of beta-carbolines in rats trained with ibogaine as a discriminative stimulus. European Journal of Pharmacology.

Itzhak & Ali (1998). Effect of ibogaine on the various sites of the NMDA receptor complex and sigma binding sites in rat brain. Annals of the New York Academy of Sciences.

Jones, Li & Balster (1998). Failure of ibogaine to produce phencyclidine-like discriminative stimulus effects in rats and monkeys. Pharmacology, Biochemistry and Behavior.

Luciano (1998). Observations on treatment with ibogaine. The American Journal on Addictions.

Mah et al. (1998). Ibogaine acts at the nicotinic acetylcholine receptor to inhibit catecholamine release. Brain Research.

Mash et al. (1998). Medication development of ibogaine as a pharmacotherapy for drug dependence. Annals of the New York Academy of Sciences.

Obach, Pablo & Mash (1998). Cytochrome P4502D6 catalyzes the O-demethylation of the psychoactive alkaloid ibogaine to 12-hydroxyibogamine. Drug Metabolism and Disposition.

Onaivi, Ali & Chakrabarti (1998). In vivo ibogaine blockade and in vitro PKC action of cocaine. Annals of the New York Academy of Sciences.

Pablo & Mash (1998). Noribogaine stimulates naloxone-sensitive [35S]GTPgammaS binding. Neuroreport.

Rho & Glick (1998). Effects of 18-methoxycoronaridine on acute signs of morphine withdrawal in rats. Neuroreport: An International Journal for the Rapid Communication of Research in Neuroscience.

Sershen, Hashim & Lajtha (1998). Gender differences in kappa-opioid modulation of cocaine-induced behavior and NMDA-evoked dopamine release. Brain Research.

Sunder & Bhargava (1998). Enhancement of morphine antinociception by ibogaine and noribogaine in morphine-tolerant mice. Pharmacology.

Wei et al. (1998). Acute iboga alkaloid effects on extracellular serotonin (5-HT) levels in nucleus accumbens and striatum in rats. Brain Research.

Alburges & Hanson (1999). Ibogaine pretreatment dramatically enhances the dynorphin response to cocaine. Brain Research.

Alburges & Hanson (1999). Differential responses by neurotensin systems in extrapyramidal and limbic structures to ibogaine and cocaine. Brain Research.

Ali, Thiriet & Zwiller (1999). Acute ibogaine injection induces expression of the immediate early genes, egr-1 and c-fos, in mouse brain. Brain Research.

Alper et al. (1999). Treatment of acute opioid withdrawal with ibogaine. The American Journal on Addictions.

Fryer & Lukas (1999). Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. The Journal of Pharmacology and Experimental Therapeutics.

Geter-Douglass & Witkin (1999). Behavioral effects and anticonvulsant efficacies of low-affinity, uncompetitive NMDA antagonists in mice. Psychopharmacology.

Glick et al. (1999). (±)-18-Methoxycoronaridine: A novel iboga alkaloid congener having potential anti-addictive efficacy. CNS Drug Reviews.

Helsley, Rabin & Winter (1999). Further investigations of the serotonergic properties of the ibogaine-induced discriminative stimulus. Progress in Neuro-Psychopharmacology & Biological Psychiatry.

Maisonneuve & Glick (1999). Attenuation of the reinforcing efficacy of morphine by 18-methoxycoronaridine. European Journal of Pharmacology.

Moody, Monti & Spanbauer (1999). Long-term stability of abused drugs and antiabuse chemotherapeutical agents stored at -20 degrees C. Journal of Analytical Toxicology.

Morris (1999). Data accrue on "visionary" agent to interrupt addiction. The Lancet.

Szumlinski, Maisonneuve & Glick (1999). Ibogaine enhances the expression of locomotor sensitization in rats chronically treated with cocaine. Pharmacology, Biochemistry and Behavior.

Szumlinski, Maisonneuve & Glick (1999). Pretreatment with the putative anti-addictive drug, ibogaine, increases the potency of cocaine to elicit locomotor responding: A study with acute and chronic cocaine-treated rats. Psychopharmacology.

Wells, Lopez & Tanaka (1999). The effects of ibogaine on dopamine and serotonin transport in rat brain synaptosomes. Brain Research Bulletin.

Winter et al. (1999). The acute effects of monoamine reuptake inhibitors on the stimulus effects of hallucinogens. Pharmacology, Biochemistry and Behavior.

Yu et al. (1999). Ibogaine blocked methamphetamine-induced hyperthermia and induction of heat shock protein in mice. Brain Research.

Zubaran et al. (1999). Noribogaine generalization to the ibogaine stimulus: Correlation with noribogaine concentration in rat brain. Neuropsychopharmacology.

Alburges et al. (2000). Responses of the extrapyramidal and limbic substance P systems to ibogaine and cocaine treatments. European Journal of Pharmacology.

Alper et al. (2000). Ibogaine in acute opioid withdrawal. An open label case series. Annals of the New York Academy of Sciences.

Baumann et al. (2000). Noribogaine (12-hydroxyibogamine): a biologically active metabolite of the antiaddictive drug ibogaine. Annals of the New York Academy of Sciences.

Baumann, Rothman & Ali (2000). Comparative neurobiological effects of ibogaine and MK-801 in rats. Drug and Alcohol Dependence.

Binienda (2000). Application of electrophysiological method to study interactions between ibogaine and cocaine. Annals of the New York Academy of Sciences.

Glick, Maisonneuve & Szumlinski (2000). 18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action. Annals of the New York Academy of Sciences.

Glick, Maisonneuve & Dickinson (2000). 18-MC reduces methamphetamine and nicotine self-administration in rats. NeuroReport.

Hough, Bagal & Glick (2000). Pharmacokinetic characterization of the indole alkaloid ibogaine in rats. Methods and Findings in Experimental and Clinical Pharmacology.

King et al. (2000). Synthesis of enantiomerically pure (+)- and (-)-18-methoxycoronaridine hydrochloride and their preliminary assessment as anti-addictive agents. Bioorganic & Medicinal Chemistry Letters.

Leal, de Souza & Elisabetsky (2000). Long-lasting ibogaine protection against NMDA-induced convulsions in mice. Neurochemical Research.

Mash et al. (2000). Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. Annals of the New York Academy of Sciences.

Mundey et al. (2000). Pharmacological comparison of the effect of ibogaine and 18-methoxycoronaridine on isolated smooth muscle from the rat and guinea-pig. British Journal of Pharmacology.

Szumlinski, Maisonneuve & Glick (2000). The potential anti-addictive agent, 18–methoxycoronaridine, blocks the sensitized locomotor and dopamine responses produced by repeated morphine treatment. Brain Research.

Szumlinski, Maisonneuve & Glick (2000). Differential effects of ibogaine on behavioural and dopamine sensitization to cocaine. European Journal of Pharmacology.

Szumlinski et al. (2000). Interactions between 18-methoxycoronaridine (18-MC) and cocaine: Dissociation of behavioural and neurochemical sensitization. Brain Research.

Szumlinski, Maisonneuve & Glick (2000). The potential anti-addictive agent, 18-methoxycoronaridine, blocks the sensitized locomotor and dopamine responses produced by repeated morphine treatment. Brain Research.

Szumlinski et al. (2000). Interactions between iboga agents and methamphetamine sensitization: Studies of locomotion and stereotypy in rats. Psychopharmacology.

Szumlinski, Maisonneuve & Glick (2000). 18-Methoxycoronaridine differentially alters the sensitized behavioral and dopaminergic responses to repeated cocaine and morphine administration. Implications for sensitization in the mediation of drug addiction. Annals of the New York Academy of Sciences.

Vilner & Bowen (2000). Modulation of cellular calcium by sigma-2 receptors: release from intracellular stores in human SK-N-SH neuroblastoma cells. The Journal of Pharmacology and Experimental Therapeutics.